Severe Acute Respiratory Syndrome Coronavirus—2 (SARS CoV-2) has resulted in the
global spread of Coronavirus Disease 2019 (COVID-19) and an increase in complications …

The COVID-19 pandemic, caused by SARS-CoV-2, had its first cases identified in late 2019
and was considered a clinical pandemic in March 2020. In March 2022, more than 500 …

Severity of COVID-19 shows an extraordinary correlation with increasing age. We generated
a mouse model for severe COVID-19 and show that the age-dependent disease severity is …

SARS-CoV-2-infected symptomatic patients often suffer from high fever and loss of appetite
which are responsible for the deficit of fluids and of protein intake. Many patients admitted to …

Clinical and molecular heterogeneity are common features of human disease.
Understanding the basis for heterogeneity has led to major advances in therapy for many …

Over the past decade, we witnessed a promising application of cold atmospheric plasma
(CAP) in cancer therapy. The aim of this systematic review was to provide an exhaustive …

There are currently relatively few small-molecule antiviral drugs that are either approved or
emergency-approved for use against severe acute respiratory coronavirus 2 (SARS-CoV-2) …

In critically ill patients infected with SARS-CoV-2, early leukocyte recruitment to the
respiratory system was found to be orchestrated by leukocyte trafficking molecules …

There are growing concerns that some COVID-19 survivors may acquire fibrosis and other
irreversible lung abnormalities. The purpose of this prospective study was to assess the rate …

Since the beginning of the COVID-19 pandemic, clinical, radiological, and histopathological
studies have provided evidence that organizing pneumonia is a possible consequence of …